September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Variability of disease activity in patients treated with ranibizumab for neovascular age-related macular degeneration
Author Affiliations & Notes
  • Philip Enders
    Center of Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Paula Scholz
    Center of Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Philipp Muether
    Center of Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Sascha Fauser
    Center of Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Footnotes
    Commercial Relationships   Philip Enders, None; Paula Scholz, None; Philipp Muether, None; Sascha Fauser, None
  • Footnotes
    Support  This study was supported by a grant from Novartis. The sponsor had no role in design, conduct, or analysis of the study
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2666. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Philip Enders, Paula Scholz, Philipp Muether, Sascha Fauser; Variability of disease activity in patients treated with ranibizumab for neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2666.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze choroidal neovasularization (CNV) activity and recurrence patterns in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab and the correlation with individual intraocular vascular endothelial growth factor (VEGF) suppression time (VST).

Methods : Post-hoc analysis of data from a prospective, non-randomized clinical study. Patients with nAMD treated with ranibizumab on a pro re nata regimen. Disease activity was analyzed monthly by spectral-domain optical coherence tomography (SD-OCT) and correlated with VSTs.

Results : 73 eyes of 73 patients were included in the study with a mean follow-up of 717 days (range 412-1239 days). Overall, the mean CNV-activity free interval was 76.5 days (range 0 – 829 days). The individual range of the length of dry intervals was high. 42% of patients had a range of more than 90 days. 16% of patients showed persistent activity. 12 % stayed dry after the initial ranibizumab treatment. No significant correlation was found between the CNV recurrence pattern and VST (p = 0.12).

Conclusions : Conclusions: CNV activity in nAMD is irregular which is reflected in the range of the duration of dry intervals and late recurrences. Any OCT-follow up scheme screening for recurrences needs to reflect this high variability.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×